• Publications
  • Influence
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Alzheimer’s disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-basedExpand
  • 918
  • 41
Complement C3 Deficiency Leads to Accelerated Amyloid β Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice
Complement factor C3 is the central component of the complement system and a key inflammatory protein activated in Alzheimer's disease (AD). Previous studies demonstrated that inhibition of C3 byExpand
  • 225
  • 7
Minocycline affects microglia activation, Aβ deposition, and behavior in APP‐tg mice
Activated microglia and reactive astrocytes invade and surround cerebral β amyloid (Aβ) plaques in Alzheimer's disease (AD), but the role of microglia in plaque development is still unclear. In thisExpand
  • 159
  • 5
Short Amyloid-β (Aβ) Immunogens Reduce Cerebral Aβ Load and Learning Deficits in an Alzheimer's Disease Mouse Model in the Absence of an Aβ-Specific Cellular Immune Response
Amyloid-β (Aβ) immunotherapy lowers cerebral Aβ and improves cognition in mouse models of Alzheimer's disease (AD). A clinical trial using active immunization with Aβ1–42 was suspended after ∼6% ofExpand
  • 140
  • 2
Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans.
Alzheimer disease (AD), the most common form of dementia, is without an effective cure or preventive treatment. Recently, amyloid-beta protein (Abeta) has become a major therapeutic target. ManyExpand
  • 70
  • 1
Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G).
Abeta vaccination or passive transfer of human-specific anti-Abeta antibodies are approaches under investigation to prevent and/or treat Alzheimer's disease (AD). Successful active Abeta vaccinationExpand
  • 41
Novel Aβ Immunogens: Is Shorter Better?
Active and passive Aβ immunotherapy in Alzheimers disease (AD)-like mouse models lowers cerebral amyloid- β protein (Aβ) levels, especially if given early in the disease process, and improvesExpand
  • 23
Developing Novel Immunogens for an Effective, Safe Alzheimer’s Disease Vaccine
Active amyloid β (Aβ) vaccination has been shown to be effective in clearing cerebral Aβ and improving cognitive function in mouse models of Alzheimer’s disease. However, an Aβ vaccine clinical trialExpand
  • 25
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
This corrects the article DOI: 10.1038/nature21361
  • 15
Novel Abeta immunogens: is shorter better?
Active and passive Abeta immunotherapy in Alzheimer's disease (AD)-like mouse models lowers cerebral amyloid-beta protein (Abeta) levels, especially if given early in the disease process, andExpand
  • 19